Crispr Therapeutics (NASDAQ:CRSP) was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.
A number of other research firms have also weighed in on CRSP. restated a “hold” rating on shares of Crispr Therapeutics in a report on Monday, September 17th. Needham & Company LLC started coverage on Crispr Therapeutics in a report on Friday, November 30th. They set a “buy” rating and a $62.00 target price for the company. Zacks Investment Research upgraded Crispr Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 target price for the company in a report on Thursday, January 3rd. Wells Fargo & Co started coverage on Crispr Therapeutics in a report on Wednesday, October 10th. They set an “outperform” rating and a $65.00 target price for the company. Finally, SunTrust Banks restated a “buy” rating on shares of Crispr Therapeutics in a report on Monday, December 31st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $59.19.
Shares of NASDAQ CRSP traded up $0.58 during trading hours on Thursday, reaching $35.15. The stock had a trading volume of 446,591 shares, compared to its average volume of 1,017,600. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of -20.56 and a beta of 3.48. Crispr Therapeutics has a 52-week low of $22.22 and a 52-week high of $73.90.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.33). The firm had revenue of $0.56 million during the quarter, compared to analysts’ expectations of $2.64 million. Crispr Therapeutics had a negative net margin of 331.84% and a negative return on equity of 40.41%. The firm’s revenue for the quarter was down 76.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.62) EPS. Equities research analysts anticipate that Crispr Therapeutics will post -3.26 earnings per share for the current year.
In related news, Director Kurt Von Emster sold 72,934 shares of the company’s stock in a transaction on Tuesday, December 18th. The stock was sold at an average price of $29.85, for a total value of $2,177,079.90. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, President Rodger Novak sold 17,310 shares of the company’s stock in a transaction on Tuesday, January 8th. The shares were sold at an average price of $35.09, for a total value of $607,407.90. Following the completion of the transaction, the president now directly owns 1,130,697 shares in the company, valued at $39,676,157.73. The disclosure for this sale can be found here. In the last quarter, insiders have bought 153,682 shares of company stock valued at $3,700,718. Company insiders own 37.70% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc increased its position in shares of Crispr Therapeutics by 6.6% in the 3rd quarter. Vanguard Group Inc now owns 52,023 shares of the company’s stock valued at $2,307,000 after acquiring an additional 3,200 shares during the period. Federated Investors Inc. PA increased its position in shares of Crispr Therapeutics by 21.0% in the 3rd quarter. Federated Investors Inc. PA now owns 764,263 shares of the company’s stock valued at $33,895,000 after acquiring an additional 132,863 shares during the period. Vanguard Group Inc. increased its position in shares of Crispr Therapeutics by 6.6% in the 3rd quarter. Vanguard Group Inc. now owns 52,023 shares of the company’s stock valued at $2,307,000 after acquiring an additional 3,200 shares during the period. Morgan Stanley increased its position in shares of Crispr Therapeutics by 18.4% in the 3rd quarter. Morgan Stanley now owns 232,540 shares of the company’s stock valued at $10,313,000 after acquiring an additional 36,098 shares during the period. Finally, Luminus Management LLC acquired a new stake in Crispr Therapeutics during the 3rd quarter worth about $5,974,000. 43.81% of the stock is currently owned by hedge funds and other institutional investors.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.
Recommended Story: Leveraged Buyout (LBO) Explained
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.